BioNTech vs Guardant Health
BioNTech (BNTX), health care, and Guardant Health (GH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BioNTech is worth $21B on the stock market and Guardant Health $19.4B: BioNTech is valued at 9% more. BioNTech's operating margin in its latest fiscal year was -49.0% and Guardant Health's -44.5%. Over the past year BioNTech's share price has moved -16.8% and Guardant Health's +50.7%.
Key facts
- BioNTech market value
- $21B
- Guardant Health market value
- $19.4B
- BioNTech revenue
- $3.2BFY to 2025-12-31
- Guardant Health revenue
- $982MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | BioNTech | Guardant Health |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $21Bhigher | $19.4Blower |
| Revenue | $3.2Bhigher | $982Mlower |
| Earnings | -$1.3Blower | -$416.3Mhigher |
| Employees | 7,807higher | 2,490lower |
| Total assets | $24.4Bhigher | $2Blower |
| Valuation | ||
| P/E | — | — |
| P/S | 6.6lower | 19.7higher |
| P/B | — | — |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | -49.0%lower | -44.5%higher |
| Balance sheet | ||
| Net assets | $21.3Bhigher | -$99.3Mlower |
| Total liabilities | $3.1Bhigher | $2.1Blower |
| Total debt | — | $1.5B |
| Cash on hand | $8.5Bhigher | $378.2Mlower |
| Price change | ||
| Today | -0.47%higher | -0.52%lower |
| 1 year | -16.8%lower | +50.7%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Percentages are each holding's share of that investor's reported portfolio (under "Both": BioNTech / Guardant Health). Who owns BNTX · Who owns GH
More on BioNTech
Further comparisons
BioNTech against its closest peers
Guardant Health against its closest peers
Learn
Questions and answers
Which is bigger, BioNTech or Guardant Health?
By market value, BioNTech is the larger: $21B against $19.4B for Guardant Health. By revenue in its latest fiscal year, BioNTech is the larger: $3.2B against $982M for Guardant Health.
Which has the higher operating margin?
Guardant Health: -44.5%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both BioNTech and Guardant Health?
In their latest 13F filings, Temasek holds both.
Cite this page
Funkfolio, “BioNTech vs Guardant Health”, data as of 17 November 2026. https://funkfolio.com/compare/bntx-vs-gh
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.